3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pancreatic Neoplasms
295
Carcinoma, Non-Small-Cell Lung
160
Lung Neoplasms
89
Breast Neoplasms
84
Urinary Bladder Neoplasms
83
Cholangiocarcinoma
58
Neoplasms
53
Neoplasm Metastasis
51
Ovarian Neoplasms
45
Biliary Tract Neoplasms
45
Lymphoma, Large B-Cell, Diffuse
32
Lymphoma
30
Sarcoma
29
Hodgkin Disease
28
Recurrence
26
Nasopharyngeal Carcinoma
26
Gallbladder Neoplasms
26
Carcinoma, Transitional Cell
26
Adenocarcinoma
22
Triple Negative Breast Neoplasms
20
Fallopian Tube Neoplasms
20
Bile Duct Neoplasms
20
Adenocarcinoma of Lung
20
Carcinoma, Renal Cell
17
Carcinoma, Ovarian Epithelial
16
Urethral Neoplasms
15
Lymphoma, Non-Hodgkin
15
Colorectal Neoplasms
14
Leiomyosarcoma
13
Kidney Neoplasms
13
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gemcitabine
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled